Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 8, 2012 - Issue 8
Submit an article Journal homepage
117
Views
9
CrossRef citations to date
0
Altmetric
Drug Profile

Belatacept: a novel immunosuppressive agent for kidney transplant recipients

Bernard Charpentier University Hospital of Bicêtre, 78 Rue du Général Leclerc, 94275 Kremlin-Bicêtre, France, Research Unit, INSERM/University Paris-Sud, 11 U 1014, France. [email protected]; University Hospital of Bicêtre, 78 Rue du Général Leclerc, 94275 Kremlin-Bicêtre, France, Research Unit, INSERM/University Paris-Sud, 11 U 1014, France. [email protected]
Pages 719-728 | Published online: 10 Jan 2014

References

  • Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am. J. Transplant. 11(3), 450–462(2011).
  • Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N. Engl. J. Med. 349(24), 2326–2333 (2003).
  • Solez K, Colvin RB, Racusen LC et al. Banff ‘05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’). Am. J. Transplant. 7(3), 518–526 (2007).
  • Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int. 62(1), 311–318 (2002).
  • Matas AJ. Chronic progressive calcineurin nephrotoxicity: an overstated concept. Am. J. Transplant. 11(4), 687–692 (2011).
  • Chapman JR. Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am. J. Transplant. 11(4), 693–697 (2011).
  • Gaston RS, Cecka JM, Kasiske BL et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 90(1), 68–74 (2010).
  • Nankivell BJ, Alexander SI. Rejection of the kidney allograft. N. Engl. J. Med. 363(15), 1451–1462 (2010).
  • Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat. Rev. Immunol. 2(2), 116–126 (2002).
  • Gross JA, Callas E, Allison JP. Identification and distribution of the costimulatory receptor CD28 in the mouse. J. Immunol. 149(2), 380–388 (1992).
  • Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 4(6), 535–543 (1996).
  • Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu. Rev. Immunol. 23, 515–548 (2005).
  • Aruffo A, Seed B. Molecular cloning of a CD28 cDNA by a high-efficiency COS cell expression system. Proc. Natl Acad. Sci. USA 84(23), 8573–8577 (1987).
  • Gross JA, St John T, Allison JP. The murine homologue of the T lymphocyte antigen CD28. Molecular cloning and cell surface expression. J. Immunol. 144(8), 3201–3210 (1990).
  • Brunet JF, Denizot F, Luciani MF et al. A new member of the immunoglobulin superfamily – CTLA-4. Nature 328(6127), 267–270 (1987).
  • Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174(3), 561–569 (1991).
  • Greene JL, Leytze GM, Emswiler J et al. Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions. J. Biol. Chem. 271(43), 26762–26771 (1996).
  • Akalin E, Chandraker A, Russell ME, Turka LA, Hancock WW, Sayegh MH. CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell-mediated and humoral immune responses in vivo. Transplantation 62(12), 1942–1945 (1996).
  • Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381(6581), 434–438 (1996).
  • Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP. Transplantation tolerance induced by CTLA4–Ig. Transplantation 57(12), 1701–1706 (1994).
  • Turka LA, Linsley PS, Lin H et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl Acad. Sci. USA 89(22), 11102–11105 (1992).
  • Levisetti MG, Padrid PA, Szot GL et al. Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J. Immunol. 159(11), 5187–5191 (1997).
  • Kirk AD, Harlan DM, Armstrong NN et al. CTLA4–Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl Acad. Sci. USA 94(16), 8789–8794 (1997).
  • Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4–Ig with potent immunosuppressive properties. Am. J. Transplant. 5(3), 443–453 (2005).
  • Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1), 111–122 (2007).
  • He S, Zhou Z, Liu Y et al. Do dietary betaine and the antibiotic florfenicol influence the intestinal autochthonous bacterial community in hybrid tilapia (Oreochromis niloticus ♀ × O. aureus ♂)? World J. Microbiol. Biotechnol. 28(3), 785–791 (2012).
  • Latek R, Fleener C, Lamian V et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 87(6), 926–933 (2009).
  • Guo F, Iclozan C, Suh WK, Anasetti C, Yu XZ. CD28 controls differentiation of regulatory T cells from naive CD4 T cells. J. Immunol. 181(4), 2285–2291 (2008).
  • Tang Q, Henriksen KJ, Boden EK et al. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J. Immunol. 171(7), 3348–3352 (2003).
  • Bluestone JA, Liu W, Yabu JM et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am. J. Transplant. 8(10), 2086–2096 (2008).
  • Furuzawa-Carballeda J, Lima G, Uribe-Uribe N et al. High levels of IDO-expressing CD16+ peripheral cells, and Tregs in graft biopsies from kidney transplant recipients under belatacept treatment. Transplant. Proc. 42(9), 3489–3496 (2010).
  • Chavez H, Beaudreuil S, Abbed K et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. Transpl. Immunol. 17(4), 243–248 (2007).
  • Grimbert P, Audard V, Diet C et al. T-cell phenotype in protocol renal biopsy from transplant recipients treated with belatacept-mediated co-stimulatory blockade. Nephrol. Dial. Transplant. 26(3), 1087–1093 (2011).
  • Álvarez-Quiroga C, Abud-Mendoza C, Doníz-Padilla L et al. CTLA-4-Ig therapy diminishes the frequency but enhances the function of Treg cells in patients with rheumatoid arthritis. J. Clin. Immunol. 31(4), 588–595 (2011).
  • Riella LV, Liu T, Yang J et al. Deleterious effect of CTLA4–Ig on a Treg-dependent transplant model. Am. J. Transplant. 12(4), 846–855 (2012).
  • Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 77(9), 1859–1870 (1991).
  • Ganguly BJ, Kulbokas EJ, Brickman D et al. A comparison of the peripheral blood mRNA transcriptional profiles of belatacept- and cyclosporine-treated renal transplant patients. Transplant. Int. 24(Suppl. S2), Abstract MO-041, 116 (2011).
  • Shen J, Gelb JS, Townsend RM et al. Rationale for belatacept less-intensive (LI) regimen in renal transplant recipients. Transplant. Int. 24(Suppl. s2), Abstract P-103, 255 (2011).
  • Zhou Z, Shen J, Kaul K, Pfister M, Roy A. Belatacept population pharmacokinetics in renal transplant patients. Am. J. Transplant. 10(Suppl. 4), Abstract 1505, 467 (2010).
  • Vincenti F, Larsen C, Durrbach A et al.; Belatacept Study Group. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353(8), 770–781 (2005).
  • Vincenti F, Blancho G, Durrbach A et al. Five-year safety and efficacy of belatacept in renal transplantation. J. Am. Soc. Nephrol. 21(9), 1587–1596 (2010).
  • Vincenti F, Charpentier B, Vanrenterghem Y et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am. J. Transplant. 10(3), 535–546 (2010).
  • Vincenti F, Larsen CP, Alberu J et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am. J. Transplant. 12(1), 210–217 (2012).
  • Pestana JO, Grinyo JM, Vanrenterghem Y et al. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am. J. Transplant. 12(3), 630–639 (2012).
  • Schnitzler MA, Lentine KL, Axelrod D et al. Use of 12-month renal function and baseline clinical factors to predict long-term graft survival: application to BENEFIT and BENEFIT-EXT trials. Transplantation 93(2), 172–181 (2012).
  • Durrbach A, Pestana JM, Pearson T et al. A Phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am. J. Transplant. 10(3), 547–557 (2010).
  • Florman S, Bresnahan B, Chan L et al. Three year outcomes in Black/African American kidney transplant recipients from the BENEFIT and BENEFIT-EXT studies. Am. J. Transplant. (Suppl. 2), Abstract 1091, 350 (2011).
  • Florman S, Becker T, Bresnahan B et al. Three-year outcomes by donor type in phase III studies of belatacept vs cyclosporine in kidney transplantation BENEFIT & BENEFIT-EXT. Am. J. Transplant. 11 (Suppl. 2), Abstract 229, 100 (2011).
  • Rostaing L, Reyes-Acevedo R, Neumayer HH et al. Outcomes at 3 years in kidney transplant recipients with pre-transplant diabetes from two phase 3 belatacept studies. Transplant. Int. 24(Suppl. s2), Abstract O-243 (2011).
  • Rostaing L, Massari P, Garcia VD et al. Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized Phase II study. Clin. J. Am. Soc. Nephrol. 6(2), 430–439 (2011).
  • Grinyo J, Nainan G, del Rial M et al. Renal function at 2 years in kidney transplant recipients switched from cyclosporine or tacrolimus to belatacept: results from the long-term extension of a Phase II study. Transplant. Int. 24(Suppl. s2), Abstract O-245, 70 (2011).
  • Ferguson R, Grinyó J, Vincenti F et al. Immunosuppression with belatacept-based, corticosteroid-avoiding regimens in de novo kidney transplant recipients. Am. J. Transplant. 11(1), 66–76 (2011).
  • Haggerty HG, Proctor SJ. Chronic administration of belatacept, a T-cell costimulatory signal blocker, in cynomolgus monkeys. Toxicol. Sci. 127(1), 159–168 (2012).
  • Grinyó J, Charpentier B, Pestana JM et al. An integrated safety profile analysis of belatacept in kidney transplant recipients. Transplantation 90(12), 1521–1527 (2010).
  • Vanrenterghem Y, Bresnahan B, Campistol J et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 91(9), 976–983 (2011).
  • Lee PC, Zhu L, Terasaki PI, Everly MJ. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 88(4), 568–574 (2009).
  • Terasaki PI, Cai J. Human leukocyte antigen antibodies and chronic rejection: from association to causation. Transplantation 86(3), 377–383 (2008).
  • Everly MJ, Everly JJ, Arend LJ et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am. J. Transplant. 9(5), 1063–1071 (2009).
  • Larsen CP, Bray R, Gebel H, Ganguly B, Kulbokas EJ, Brickman D. Evaluation of donor-specific antibodies in kidney transplant patients treated with belatacept- or cyclosporine-based immunosuppression in BENEFIT and BENEFIT-EXT. Transplant. Int. 24(Suppl. S2), Abstract O-244.
  • Gill JS, Landsberg D, Johnston O et al. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection. Transplantation 89(2), 178–184 (2010).
  • Zhang Q, Liang LW, Gjertson DW et al. Development of posttransplant antidonor HLA antibodies is associated with acute humoral rejection and early graft dysfunction. Transplantation 79(5), 591–598 (2005).
  • Hourmant M, Cesbron-Gautier A, Terasaki PI et al. Frequency and clinical implications of development of donor-specific and non-donor-specific HLA antibodies after kidney transplantation. J. Am. Soc. Nephrol. 16(9), 2804–2812 (2005).
  • Archdeacon P, Dixon C, Belen O, Albrecht R, Meyer J. Summary of the US FDA approval of belatacept. Am. J. Transplant. 12(3), 554–562 (2012).
  • Fine RN, Becker Y, De Geest S et al. Nonadherence consensus conference summary report. Am. J. Transplant. 9(1), 35–41 (2009).
  • Cibrik D, Steinberg S, West P et al. A phase 2 study to assess the safety and efficacy of alefacept (alef) in de novo kidney transplant recipients. Transplant. Int. 24(Suppl. s2), Abstract O-24770 (2011).
  • Vincenti F, Tedesco Silva H, Busque S et al. Efficacy and safety of CP-690,550-MPA combination regimens in de novo kidney transplant patients: 12-month final results of a phase 2b study. Am. J. Transplant. 11(30), Abstract 4 (2011).
  • Larsen CP, Knechtle SJ, Adams A, Pearson T, Kirk AD. A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. Am. J. Transplant. 6(5 Pt 1), 876–883 (2006).
  • Furuzawa-Carballeda J, Lima G, Alberú J et al. Infiltrating cellular pattern in kidney graft biopsies translates into forkhead box protein 3 up-regulation and p16INK4a senescence protein down-regulation in patients treated with belatacept compared to cyclosporin A. Clin. Exp. Immunol. 167(2), 330–337 (2012).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.